Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Share:
Related LGND
Benzinga's Top Upgrades, Downgrades For September 5, 2017
Analyst Makes The Case For Ligand As A 'Core' Holding
Related GSK
The Week Ahead: Earnings Season Starts In Earnest
Attention Biotech Investors, Here's Your PDUFA Primer For October

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA

 

Related Articles (LGND + GSK)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...